What Causes Low SDMA on Lab Tests?

← Back to Clinical Articles

Article: What Causes Low SDMA on Lab Tests?  |  Category: Metabolic  |  Authored by: Brian Lamkin, DO

What SDMA Is and Why It Appears on Functional Panels

SDMA (symmetric dimethylarginine) is a naturally occurring amino acid derivative produced when arginine residues on intracellular proteins are methylated by protein arginine methyltransferases (PRMTs)^[1]. When these methylated proteins are broken down through normal protein turnover, SDMA is released into the bloodstream. Unlike its asymmetric counterpart ADMA (which is partially metabolized by the enzyme DDAH), SDMA is not significantly metabolized. It is cleared almost exclusively by glomerular filtration in the kidneys. This makes it a relatively pure marker of glomerular filtration rate (GFR). It has long been used in veterinary medicine as an early renal biomarker and is now appearing more frequently on comprehensive human functional medicine panels alongside BUN, creatinine, and cystatin C.

How SDMA Differs From Creatinine

Creatinine is produced from creatine phosphate breakdown in muscle tissue. This means creatinine levels are heavily influenced by muscle mass, dietary creatine intake (particularly red meat), recent exercise, and age. A muscular 25-year-old man and a frail 80-year-old woman with the same creatinine value almost certainly have very different GFRs. SDMA is produced from protein methylation in all nucleated cells, not just muscle. While it is still influenced by protein turnover and muscle mass to some degree, this influence is significantly less than creatinine. SDMA is not secreted by the renal tubules the way creatinine partially is^[2], which makes it a more specific marker of true glomerular filtration. In practical terms: creatinine can overestimate GFR in patients with low muscle mass (because less creatinine is produced, making the level appear deceptively normal despite reduced filtration). SDMA is less susceptible to this bias, though not completely immune to it.

What Low SDMA Typically Means

Low SDMA is an uncommon finding, and when it appears, it almost always reflects reduced protein turnover rather than exceptionally good kidney function. The primary causes of low SDMA in clinical practice are low muscle mass (sarcopenia), inadequate dietary protein intake, cachexia from chronic illness, severe caloric restriction or prolonged fasting, and rarely, normal individual variation in patients who are otherwise healthy. The mechanism is straightforward: less protein in the body means fewer arginine residues being methylated, which means less SDMA produced, which means lower serum levels. This is analogous to how low creatinine can reflect low muscle mass rather than excellent kidney function.

The Low SDMA Plus Low Creatinine Plus Low BUN Pattern

When all three renal markers are low simultaneously, the pattern strongly suggests reduced protein turnover rather than any primary renal issue. This is the pattern seen in patients who are not consuming adequate protein, who have lost significant muscle mass (from aging, inactivity, weight loss on GLP-1 medications without resistance training, or chronic illness), or who are in a catabolic state. In functional medicine, this triple-low pattern prompts evaluation of protein adequacy, muscle mass, and nutritional status before any renal concern is considered.

When Low SDMA Warrants Further Evaluation

Low SDMA in a patient who is unintentionally losing weight warrants workup for underlying malignancy, chronic infection, thyroid dysfunction, or other causes of wasting. Low SDMA in a patient on an aggressive weight-loss program (particularly without adequate protein intake or resistance training) signals that lean mass loss is likely occurring and the protocol needs adjustment. Low SDMA in a patient with normal body composition and normal nutrition is likely normal variation and does not typically require intervention. Low SDMA with normal or elevated creatinine is a discrepant pattern that may warrant further renal evaluation (cystatin C, renal ultrasound), as it could reflect an unusual combination of low protein turnover with early renal impairment masked by the low SDMA.

SDMA in the Context of GLP-1 Weight Loss

One increasingly common clinical scenario where low SDMA appears is in patients losing weight on GLP-1 receptor agonists without adequate muscle preservation protocol. As discussed in our GLP-1 article, up to 40 percent of weight lost on semaglutide or tirzepatide can be lean muscle mass if protein intake and resistance training are not prioritized. A declining SDMA during GLP-1 treatment, particularly alongside declining creatinine, is an objective signal that muscle mass is being lost. Body composition analysis (DEXA) confirms the finding. This is one reason The Lamkin Clinic monitors body composition and renal markers during all weight-loss interventions.

SDMA and Chronic Kidney Disease

While this article focuses on low SDMA, it is worth noting the more common clinical scenario: elevated SDMA as an early marker of renal dysfunction^[3]. In veterinary medicine, SDMA rises earlier than creatinine during kidney function decline because it is not subject to tubular secretion. In human medicine, SDMA is increasingly used alongside cystatin C as a GFR marker that is less muscle-mass-dependent than creatinine. Patients with type 2 diabetes and insulin resistance are at highest risk for progressive renal decline, making SDMA monitoring particularly relevant in metabolic patients. When SDMA is elevated and creatinine is normal, it may indicate early renal dysfunction that creatinine has not yet detected. When SDMA is low and creatinine is normal, it typically reflects the protein turnover issue discussed above rather than a renal concern.

The Protein Connection

Low SDMA should always prompt a protein assessment. Inadequate protein intake is one of the most under-recognized nutritional deficiencies in otherwise health-conscious patients. Patients pursuing plant-based diets, patients restricting calories for weight loss, elderly patients with reduced appetite, and patients on medications that suppress hunger (including GLP-1 agonists) are all at risk. The functional medicine recommendation for most adults is 0.8 to 1.2 grams of protein per kilogram of body weight as a minimum, with 1.2 to 1.6 grams per kilogram for patients actively trying to preserve or build muscle. When low SDMA appears alongside clinical signs of inadequate protein (hair thinning, slow wound healing, reduced strength, low albumin), increasing protein intake is the primary intervention.

Related Markers to Evaluate Alongside Low SDMA

When SDMA is low, the following markers should be interpreted in context: creatinine (also muscle-mass dependent; if both are low, protein status is the likely driver); BUN (reflects protein intake and turnover more directly than SDMA or creatinine); albumin and prealbumin (markers of visceral protein status and nutritional adequacy); total protein (broad indicator of protein balance); cystatin C (GFR marker independent of muscle mass; if cystatin C GFR is normal, renal function is reassuring despite low SDMA); and body composition analysis (DEXA or bioimpedance) to directly measure lean mass.

The Lamkin Clinic Approach

Low SDMA at The Lamkin Clinic is interpreted as a protein turnover signal, not a standalone renal marker. When SDMA is low, we evaluate dietary protein intake, body composition (lean mass versus fat mass), full renal panel including cystatin C, nutritional markers (albumin, prealbumin, total protein), and clinical context (weight loss trajectory, medication effects, chronic illness). If the pattern points to inadequate protein intake or muscle mass loss, intervention focuses on protein optimization, resistance training prescription, and addressing any underlying cause of wasting or malnutrition. If the pattern is discrepant (low SDMA with abnormal creatinine or cystatin C), further renal evaluation follows.

The Lamkin Clinic, Edmond Oklahoma | lamkinclinic.com

Frequently Asked Questions

Related Conditions

Related Clinical Articles

References and Further Reading

1. [1]Bedford MT, Clarke SG. Protein arginine methylation in mammals: who, what, and why. Mol Cell. 2009;33(1):1-13.
2. [2]Kielstein JT, et al. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function. Nephrol Dial Transplant. 2006;21(9):2446-2451.
3. [3]Schwedhelm E, Boger RH. The role of asymmetric and symmetric dimethylarginines in renal disease. Nat Rev Nephrol. 2011;7(5):275-285.